Genelabs Technologies (GNLB) Collaboration with Novartis on Hepatitis C Drug Development Continues to Next Phase

June 23, 2008 9:20 AM EDT

Genelabs Technologies, Inc. (Nasdaq: GNLB) today announced that its hepatitis C drug development and commercialization collaboration with Novartis (NYSE: NVG) is continuing to the next phase.

In September 2006, Genelabs and Novartis entered into a two-year collaboration to discover and develop certain non-nucleoside inhibitors of the NS5b polymerase in HCV. Genelabs was responsible for drug discovery research and Novartis is responsible for development and commercialization. The research phase of the collaboration was completed on June 2, 2008. Genelabs and Novartis will continue to hold joint research committee meetings to monitor the progress of compounds discovered during this phase as they advance.

Additionally, Genelabs has announce that Gilead Sciences (Nasdaq: GILD) has exercised its right to terminate a similar research collaboration agreement for nucleoside-based inhibitors for the NS5b HCV polymerase, and will return to Genelabs all rights to the compounds developed in the program.

Genelabs Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of infectious disease therapies to improve human health.

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?